has designated the allosteric AKT-inhibitor VAD044 a Fast Track product for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT). Fast Track is an FDA process designed to facilitate the ...
Some results have been hidden because they may be inaccessible to you